Get started
Author

Alexander Link

Observed name: Alexand Link
ORCID: 0009-0004-0545-3161
Observed ORCID: 0009-0004-0545-3161
OpenAlex ID: A5114626383
Cholangiocarcinoma 2026: status quo, unmet needs and priorities
2025 · Jesus M. Banales, Pedro M. Rodrigues, et al. · Nature Reviews Gastroenterology & Hepatology · 123
PDF
Single-cell insights into tumor microenvironment heterogeneity and plasticity: transforming precision therapy in gastrointestinal cancers
2025 · Jialei Weng, Feng Ju, et al. · Journal of Experimental & Clinical Cancer Research · 27
PDF
Abstract 3752: Preclinical pharmacology of MP0310: A 4-1BB/FAP bispecific DARPin drug candidate promoting tumor-restricted T-cell costimulation
2018 · Alexander Link, Julia Hepp, et al. · Cancer Research · 7
Improvement of daratumumab- or elotuzumab-mediated NK cell activity by the bi-specific 4-1BB agonist, DARPin α-FAPx4–1BB: A preclinical study in multiple myeloma
2024 · Ilaria Saltarella, Alexander Link, et al. · Biomedicine & Pharmacotherapy · 4
PDF
Abstract 2273: Selection of first-in-human clinical dose range for the tumor-targeted 4-1BB agonist MP0310 (AMG 506) using a pharmacokinetic/pharmacodynamics modeling approach
2020 · Alexander Link, Laurent Juglair, et al. · Cancer Research · 4
Abstract 3029: FAP-mediated tumor accumulation of a T-cell agonistic FAP/4-1BB DARPin drug candidate analyzed by SPECT/CT and quantitative biodistribution
2018 · Christian Reichen, Ralph Bessey, et al. · Cancer Research · 3
Abstract 3119: Next-generation multi-specific and conditionally activated CD3 Switch-DARPins with CD2 co-stimulation to tackle the current limitations of T cell engagers in solid tumors
2025 · Matteo Bianchi, Marco Franchini, et al. · Cancer Research · 1
MP0621 (cKit x CD16a x CD47), a Multi-Specific Switch-Darpin with Conditional Blockade of CD47 Targeting Hematopoietic Stem Cells: Preclinical Evaluation of a Next-Generation Conditioning Agent for Stem Cell Transplantation
2024 · Alexander Link, Teresa Maria Frasconi, et al. · Blood · 1
PDF
Abstract B026: Development of tumor-targeted agonistic Immunomodulators using the DARPin® technology platform
2019 · Victor Levitsky, Alexand Link, et al. · Cancer Immunology Research · 1
Abstract 4552: Tumor-restricted immune modulation by multispecific molecules from the DARPin toolbox
2018 · Ulrike Fiedler, Christian Reichen, et al. · Cancer Research · 1
Comparison of an FAP-targeted, CD137 activating DARPin drug candidate with a non-targeted, CD137 activating antibody in a human PBMC transplanted HT-29 mouse tumor model.
2017 · Julia Hepp, Alexander Link, et al. · Journal of Clinical Oncology · 1
1072 MP0632, a logic-gated conditional Switch-DARPin T cell engager with CD2 co-stimulation enabling selective activity against solid tumors co-expressing MSLN and EpCAM
2026 · Stephan Wullschleger, Matteo Bianchi, et al. · Journal for ImmunoTherapy of Cancer
PDF
Abstract 2691: Logic-gated Switch-DARPin-based immune cell engagers guided by data-driven tumor-antigen profiling: A computational workflow for the development of cancer immunotherapies.
2026 · Albulena Toska, Ana Maria Florescu, et al. · Cancer Research
Abstract 1624: Logic-gated switch-DARPin T cell engager with CD2 co-stimulation for improved safety and efficacy in MSLN and EpCAM co-expressing ovarian cancer
2026 · Matteo Bianchi, Sarah Jetzer, et al. · Cancer Research
829 A next-generation conditional Switch-DARPin T cell engager with CD2 co-stimulation enabling selective activity against solid tumors which co-express mesothelin (MSLN) and EpCAM
2025 · Matteo Bianchi, Joanna Robinson, et al. · Journal for ImmunoTherapy of Cancer
PDF
Works count: 15
Citation count: 173
H-index: 4
I10-index: 2
Year
Topic
Type